論文（2013 年以降）
1.

Nakashima H, Henmi T, Minami K, Uchida Y, Shiraishi Y, Nunohiro T, Maemura K:
Obstructive sleep apnoea increases the incidence of morning peak of onset in acute
myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2(2): 153-8, 2013.

2.

Nakashima H, Umeyama Y, Minami K: Successive immunosuppressive treatment offulminant myocarditis that is refractory to mechanical circulatory support. Am J Case Rep.
23: 116-119, 2013.

3.

Kario K, Ando S, Kido H, Nariyama J, Takiuchi S, Yagi T, Shimizu T, Eguchi K, Ohno
M, Kinoshita O, Yamada T, APPENDIX Nunohiro T. The effects of the L/N-typecalcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension:
results from ACHIEVE-ONE. Journal of Clinical Hypertension 2013 Feb; 15(2): 133-42.

4.

White WB, Cannon CP, Heller SR; EXAMINE Investigators, Collaborators Nunohiro T.
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med.
2013 Oct 3; 369(14): 1327-35.

5.

Hokusai-VTE Investigators, Büller HR, Décousus H, Wells P, Collaborators Nunohiro T.
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
N Engl J Med. 2013 Oct 10; 369(15): 1406-15.

6.

Uchida Y, Nakashima H, Takeshita S: Modified mother-child technique using a buddy
wire. J Invasive Cardiol. 26(5): E52-3, 2014.

7.

Pieske B, Butler J, Gheorghiade M; SOCRATES Investigators and Coordinators,
Collaborators Nunohiro T. Rationale and design of the SOluble guanylate CyclasestimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014 Sep; 16(9):1026-38.

8.

Nakashima H, Kurobe M, Minami K, Furudono S, Uchida Y, Amenomori K, Nunohiro T,Takeshita S, Maemura K: Effects of moderate-to-severe obstructive sleep apnea on theclinical manifestations of plaque vulnerability and the progression of coronary
atherosclerosis in patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc
Care.4(1):75-84,2015.

9.

Bentley-Lewis R, Aguilar D, McMurray JJ, Ping L, Probstfield JL, Solomon SD, TardifJC, Wu Y, Pfeffer MA; ELIXA Investigators, Collaborators Nunohiro T. Rationale, design,and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome,a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015
May; 169(5): 631-638.e7.

10. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P,
Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B;
SOCRATES-REDUCED Investigators and Coordinators, Collaborators Nakashima H,Nunohiro T, Furudono S. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator,
on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure andReduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA.
2015 Dec 1; 314(21): 2251-62.
11. Pfeffer MA, Claggett B, Tardif JC; ELIXA Investigators, Collaborators Nunohiro T.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl JMed. 2015 Dec 3; 373(23): 2247-57.
12. Nakashima H, Mashimo Y, Kurobe M, Muto S, Furudono S, Maemura K: Impact ofMorning Onset on the Incidence of Recurrent Acute Coronary Syndrome andProgression of Coronary Atherosclerosis in Acute Myocardial Infarction. Circ J. 81(3):361-367, 2017.
13. Sabatine MS, Giugliano RP, Pedersen TR; FOURIER Steering Committee andInvestigators, Collaborators Nunohiro T. Evolocumab and Clinical Outcomes in Patientswith Cardiovascular Disease. N Engl J Med. 2017 May 4; 376(18): 1713-1722.
14. Asakura M, Nunohiro T, Kitakaze M: Does Treatment of Impaired Glucose Tolerance
Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Cardiovasc Drugs Ther. 2017 Aug; 31(4): 401-411.
15. Zannad F, Anker SD, Byra WM; COMMANDER HF Investigators, Collaborators
Nunohiro T. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary
Disease. N Engl J Med. 2018 Oct 4; 379(14): 1332-1342.
16. McMurray JJV, Solomon SD, Inzucchi SE, Appendix Nunohiro T. Dapagliflozin inpatients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;
381: 1995-2008.
17. Armstrong PW, Pieske B, O'Connor CM; VICTORIA Study Group. Collaborators
Nunohiro T. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. NEngl J Med. 2020 May 14;382(20):1883-1893.
18. Okumura K, Akao M, Yamashita T; ELDERCARE- AF Committees and Investigators.
Collaborators Nunohiro T.Low-Dose Edoxaban in Very Elderly Patients with AtrialFibrillation. N Engl J Med. 2020 Oct 29;383(18):1735-1745
19. Docherty KF, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees.
Collaborators Nunohiro T. Effect of Dapagliflozin in DAPA-HF According toBackground Glucose-Lowering Therapy. Diabetes Care. 2020 Nov;43(11):2878-2881.

20. Lam CSP, Giczewska A, Sliwa K; VICTORIA Study Group. Collaborators Nunohiro T.
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event:Insights From the VICTORIA Trial. VICTORIA Study Group. Collaborators Nunohiro
T. JAMA Cardiol. 2021 Jun 1;6(6):706-712.
21. Docherty KF, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees.
Collaborators Nunohiro T . Extrapolating Long-term Event-Free and Overall Survival
With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: AnExploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021 Jul 28.
Online ahead of print
22. PCI 時代の急性心筋梗塞患者の来院時血糖値と長期予後の関連 布廣龍也、黒部昌也、中嶋寛 心臓 第 48 号 第 1 号（2016.1.15）
23. 房室ブロックの心電図を読む 布廣龍也 Heart View Vol.20 No.4: 90-96, 201624. 急性心筋梗塞を発症した 2 型糖尿病患者での冠動脈プラーク特性 －光干渉断層法（OCT）を用いて－ 布廣龍也、古殿真之介、中嶋寛 循環器内科, 81(2): 207-212, 201725. 1000 枚見て覚える心電図ギャラリー（電子書籍）分担執筆 布廣龍也 日本医事新報社（2018）
26. 215 症例みて覚える心電図ギャラリー（電子書籍）分担執筆 布廣龍也 日本医事新報社（2019.1.31）
27. み て 覚 え る 心 電 図 ギ ャ ラ リ ー 第 19 回 布 廣 龍 也 週 刊 日 本 医 事 新 報 No.4982（2019.10.19）
28. 福嶋理知 末永英隆 布廣龍也 前村浩二 右心室ペーシング誘発性心筋症による心 不全に対する His 束ペーシングの 1 例 心臓 2020 5：52：503－509
29. 奈良谷俊 木下和久 布廣龍也 栗山一孝 担癌状態による凝固能亢進が原因と考え られた深部静脈血栓症の 1 症例 医学検査 2021 1：70：138－143
30. みて覚える心電図ギャラリー 第６8 回 布廣龍也 週刊日本医事新報 No.5059 （2021.
４.10）
31. 急性心筋梗塞患者の高 TG 血症と small dense LDL への影響 布廣龍也 Progress inmedicine. 41：665-671,2021 7．
32. Liver stiffness assessed by Fibrosis-4 index predicts heart failure in AMI patients
T Nunohiro, K Furukawa,S Kuwasaki,S Kusumoto, S Furudono, M Takeno
European Heart Journal, Volume 43, Issue Supplement 1, February 2022, ehab849.07804
33. みて覚える 心電図ギャラリー 第 111 回 布廣龍也 週刊日本医事新法 No.5103（2022.2.12）